Dave Knapp holds up the pipeline

Dave's Friday show covers Lilly's reported $3.5 billion retatrutide plant and a stalled FDA voucher program

Dave Knapp goes through a long list of GLP-1 stories. His description says reports that the FDA's accelerated approval voucher program has stalled could matter for retatrutide and CagriSema timelines, and that Lilly is putting $3.5 billion into a new Pennsylvania plant for next-generation injectables including retatrutide. He also covers Novo's Australian price for oral Wegovy, new muscle loss research on semaglutide and tirzepatide, an experimental semaglutide implant, orforglipron Phase 3 results from Japan and the HHS six-peptide policy comment deadline. We have not watched the show, and we have not checked the $3.5 billion figure or the voucher program report. This is Dave's own content, not checked by the Atlas.

Atlas context: Our retatrutide page records it as investigational and not approved anywhere, and the late-stage drug tracker shows where the other drugs stand.

Dave's Wednesday show digs into new FDA warning letters to Chinese drug-ingredient makers

Dave Knapp's Wednesday show and newsletter post cover new FDA warning letters sent to Chinese makers of pharmaceutical ingredients. He says the FDA also previously caught a manufacturer on its GLP-1 Green List relabeling semaglutide it got from another supplier, including one that wasn't on the approved list. Dave links the three FDA letters he is working from, and says the letters do not show that specific GLP-1 medicines were involved or that the manufacturers worked together. We have not read the letters or watched the show, and we have not checked his Green List claim. This is Dave's own content, not checked by the Atlas.

Atlas context: Our guide to compounded versus brand-name medicines covers how compounded products differ from the approved drugs, including the FDA's position on semaglutide salt forms, and our online services guide explains why the medicine source matters.

Dave's Tuesday video takes on the new FDA eye warning for GLP-1 medicines

Dave Knapp's Tuesday video is titled around a new FDA warning for Zepbound and GLP-1 users. His description says the FDA issued a new eye warning for every GLP-1 medication, including Ozempic, Wegovy and Mounjaro. We went by the title and description only and have not watched the video, so we can't say what he concludes. This is Dave's own content, not checked by the Atlas.

Atlas context: Our FDA eye-warning report covers the Nov 9 notice, which calls the risk "potential," and our vision loss guide explains NAION in plain language.

Dave's Monday show takes on a 28.7% retatrutide number and its "big catch"

Dave Knapp's Monday show is titled around a 28.7% retatrutide weight-loss figure and a "big catch" attached to it. We went by the title only and have not watched the show, so we can't say which trial, dose or population the number comes from, or what the catch is. He also posted a short video on X the same day. This is Dave's own content, not checked by the Atlas.

Atlas context: Our TRIUMPH-1 report, based on the journal abstract, gives about 24% to 25% average weight loss at the two higher doses and notes retatrutide is not approved for any use. Lilly's plan to file in Q1 2027 is a company statement, on the retatrutide overview.

Dave flags a Wegovy liver-health analysis in people with a lower BMI

Dave Knapp posted about an exploratory Phase 3 analysis suggesting Wegovy might help liver health in people whose BMI is under 27, which is below the obesity range. An exploratory analysis is a secondary look at trial data, so it is a lead, not proof. This is Dave's own content, not checked by the Atlas.

Atlas context: The semaglutide overview lists Wegovy's approved uses as they stand today, including MASH with liver scarring. The Wegovy page shows that one as an accelerated approval for noncirrhotic MASH with moderate to advanced liver scarring in adults.

Dave says Novo's U.S. obesity growth leans on Medicare Bridge

Dave Knapp wrote on X that Novo Nordisk said its U.S. obesity drug growth would have been flat without the Medicare Bridge program. He compares Zepbound and Novo's U.S. obesity sales across the last two quarters and argues Novo needs bigger cash-pay discounts. These are his readings of company statements, not checked by the Atlas.

Atlas context: Our report on Lilly's Oct 29 call says more than half a million people filled a Lilly prescription through the Medicare GLP-1 Bridge, a company statement rather than independent data: Medicare Bridge uptake. Novo's side is on its business page.

A quadruple agonist beat retatrutide in rats. What that does and does not mean

Celltrion and SCOHIA Pharma showed early animal data for CT-G32 (SCO-940), a drug that hits four pathways: GLP-1, GIP, glucagon and amylin. At the same molar dose, rats lost numerically more weight than on retatrutide and lost a smaller share of it as lean mass. Dave's main point is that this is rat data, with no human efficacy or safety results yet. He reports the companies plan an FDA filing to start human testing in February 2027.

Atlas context: Our CT-G32 vs retatrutide page asks what changes when a fourth hormone pathway is added, and the late-stage tracker shows where each drug stands.

Could hackers cause the next GLP-1 shortage?

After cyberattacks drove up temperatures in supermarket freezers across Europe, Dave asks whether the refrigerated supply chain for injectable medicines could be a target. He says there is no evidence pharmacy or drug refrigerators are being targeted today. His concern is that a tampered system could force companies to quarantine stock because nobody can prove what temperature it reached. His practical tips: keep a little refill margin, and ask the pharmacist or maker before deciding whether a pen that had a temperature problem is still usable.

Atlas context: The shortage side is in our note on the appeals court ruling, which reports the Fifth Circuit upheld the FDA decisions that the semaglutide and tirzepatide shortages ended. For the makers' own pen directions, see what the brand-name pen instructions say.

HHS opens an interim path for BPC-157 and five other peptides

Dave reports that HHS has outlined a temporary policy that could let some compounding pharmacies and physicians work with six peptides without enforcement action while the formal review finishes. As he frames it, this is a bridge, not an approval and not a permanent listing. The Atlas has its own plain-language page on the policy.

Dave's full post asks readers for a free email signup.

Atlas context: Our HHS compounding policy explainer covers the six named peptides and what actually changes. See also the draft sent for White House review, what a 503A pharmacy is, and the peptide policy tracker.